Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

73.29EUR
3:48pm GMT
Change (% chg)

€0.09 (+0.12%)
Prev Close
€73.20
Open
€73.15
Day's High
€73.80
Day's Low
€73.01
Volume
1,105,839
Avg. Vol
2,118,891
52-wk High
€92.97
52-wk Low
€71.06

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €108,903.00
Shares Outstanding(Mil.): 1,262.50
Dividend: 2.96
Yield (%): 3.43

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.44
EPS (TTM): -- -- --
ROI: -- 14.85 10.61
ROE: -- 16.31 14.21

French and Benelux stocks-Factors to watch on Jan 11

Jan 11 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.

11 Jan 2018

Sanofi and Regeneron boost investment in cancer drug cemiplimab

PARIS France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.

08 Jan 2018

Sanofi and Regeneron boost investment in cancer drug cemiplimab

PARIS France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.

08 Jan 2018

Sanofi and Regeneron boost investment in cancer drug cemiplimab

PARIS, Jan 8 France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.

08 Jan 2018

BRIEF-Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 Palisade Trial Of AR101 For Peanut Allergy

* AIMMUNE THERAPEUTICS - PALISADE COMPLETED IN 2017; TOPLINE RESULTS ANTICIPATED IN FEBRUARY

08 Jan 2018

BRIEF-Sanofi And Alnylam Pharmaceuticals Enter Into Partnership

* AND ALNYLAM, ANNOUNCED ON SUNDAY STRATEGIC RESTRUCTURING OF RNAI THERAPEUTICS RARE DISEASE ALLIANCE

08 Jan 2018

Sanofi to market new hemophilia drug in deal with Alnylam

PARIS French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals.

08 Jan 2018

Sanofi to market new hemophilia drug in deal with Alnylam

PARIS, Jan 8 French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals.

08 Jan 2018

BRIEF-Evotec, Apeiron Biologics receive milestone payment from Sanofi

* SAYS ‍EVOTEC AND APEIRON ACHIEVE FIRST MILESTONE IN IMMUNO-ONCOLOGY ALLIANCE WITH SANOFI​

08 Jan 2018

Sanofi says will work with Manila in spite of Dengvaxia ban

PARIS France's Sanofi said on Thursday it would continue to cooperate with the Philippines' Food and Drug Administration after the country suspended clearance for its controversial dengue vaccine Dengvaxia.

04 Jan 2018

Earnings vs. Estimates